146 related articles for article (PubMed ID: 8248534)
1. Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease.
Davis R; Raby C; Callahan MJ; Lipinski W; Schwarz R; Dudley DT; Lauffer D; Reece P; Jaen J; Tecle H
Prog Brain Res; 1993; 98():439-45. PubMed ID: 8248534
[No Abstract] [Full Text] [Related]
2. The potential for muscarinic receptor subtype-specific pharmacotherapy for Alzheimer's disease.
McKinney M; Coyle JT
Mayo Clin Proc; 1991 Dec; 66(12):1225-37. PubMed ID: 1749291
[TBL] [Abstract][Full Text] [Related]
3. Muscarinic cholinergic agonists: pharmacological and clinical perspectives.
Palacios JM; Spiegel R
Prog Brain Res; 1986; 70():485-98. PubMed ID: 3554361
[No Abstract] [Full Text] [Related]
4. Approaches to cholinergic therapy in Alzheimer's disease.
Iversen LL
Prog Brain Res; 1993; 98():423-6. PubMed ID: 8248531
[No Abstract] [Full Text] [Related]
5. Progress in medicinal chemistry of novel selective muscarinic agonists.
Fisher A; Karton Y; Heldman E; Gurwitz D; Haring R; Meshulam H; Brandeis R; Pittel Z; Segall Y; Marciano D
Drug Des Discov; 1993; 9(3-4):221-35. PubMed ID: 8400004
[TBL] [Abstract][Full Text] [Related]
6. Neurochemical and behavioural effects of muscarinic acetylcholine receptor agonists.
Spencer DG; van Rooijen LA; Horváth E; Dompert W; Traber J
Trends Pharmacol Sci; 1988 Feb; Suppl():61-8. PubMed ID: 3074540
[No Abstract] [Full Text] [Related]
7. [Muscarine receptors and drugs; renewed interest for the parasympathetic system].
van Zwieten PA
Ned Tijdschr Geneeskd; 1994 Jan; 138(4):175-9. PubMed ID: 8107916
[No Abstract] [Full Text] [Related]
8. Regulation of intestinal motility by different muscarinic receptor subtypes.
de Ponti F; Ambrosoli L; D'Angelo L; Lecchini S; Frigo GM; Crema A
Pharmacol Res; 1989; 21 Suppl 1():89-90. PubMed ID: 2633197
[No Abstract] [Full Text] [Related]
9. [Cholinergic treatment strategies in Alzheimer's disease].
Kurz A; Rüster P; Romero B; Zimmer R
Nervenarzt; 1986 Oct; 57(10):558-69. PubMed ID: 3785472
[No Abstract] [Full Text] [Related]
10. Potential role of muscarinic agonists in Alzheimer's disease.
Avery EE; Baker LD; Asthana S
Drugs Aging; 1997 Dec; 11(6):450-9. PubMed ID: 9413702
[TBL] [Abstract][Full Text] [Related]
11. [Selective M1 muscarinic agonists: failure of therapeutic strategy against Alzheimer's disease or inappropriate tactics?].
Vamvakidès A
Ann Pharm Fr; 2003 May; 61(3):207-10. PubMed ID: 12714934
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and SAR of bulky 1-azabicyclo[2.2.1]-3-one oximes as muscarinic receptor subtype selective agonists.
Tecle H; Lauffer DJ; Mirzadegan T; Moos WH; Moreland DW; Pavia MR; Schwarz RD; Davis RE
Life Sci; 1993; 52(5-6):505-11. PubMed ID: 8382765
[TBL] [Abstract][Full Text] [Related]
13. Central pressor effects induced by muscarinic receptor agonists: evidence for a predominant role of the M2 receptor subtype.
Pazos A; Wiederhold KH; Palacios JM
Eur J Pharmacol; 1986 Jun; 125(1):63-70. PubMed ID: 3732392
[TBL] [Abstract][Full Text] [Related]
14. Selective signaling via unique M1 muscarinic agonists.
Fisher A; Heldman E; Gurwitz D; Haring R; Barak D; Meshulam H; Marciano D; Brandeis R; Pittel Z; Segal M
Ann N Y Acad Sci; 1993 Sep; 695():300-3. PubMed ID: 8239299
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and neurochemical evaluation of 2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines and 2-amino-5-(alkoxycarbonyl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists.
Dunbar PG; Durant GJ; Rho T; Ojo B; Huzl JJ; Smith DA; el-Assadi AA; Sbeih S; Ngur DO; Periyasamy S
J Med Chem; 1994 Aug; 37(17):2774-82. PubMed ID: 8064804
[TBL] [Abstract][Full Text] [Related]
16. On the physiological relevance of muscarinic acetylcholine receptors in Alzheimer's disease.
Koch HJ; Haas S; Jürgens T
Curr Med Chem; 2005; 12(24):2915-21. PubMed ID: 16305479
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of muscarinic receptors coupled to phosphoinositide breakdown in guinea pig brain and peripheral tissues.
Noronha-Blob L; Lowe VC; Hanson RC; U'Prichard DC
Life Sci; 1987 Aug; 41(8):967-75. PubMed ID: 3039279
[TBL] [Abstract][Full Text] [Related]
18. (+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease.
Fisher A; Brandeis R; Karton I; Pittel Z; Gurwitz D; Haring R; Sapir M; Levy A; Heldman E
J Pharmacol Exp Ther; 1991 Apr; 257(1):392-403. PubMed ID: 2019998
[TBL] [Abstract][Full Text] [Related]
19. Subtype of muscarinic receptor coupled to the attenuation of hormone-stimulated cAMP accumulation in NG108-15 neuroblastoma x glioma hybrid cells.
Stephan CC; Sastry BV
Cell Mol Biol (Noisy-le-grand); 1992; 38(5-6):601-12. PubMed ID: 1282846
[TBL] [Abstract][Full Text] [Related]
20. Muscarinic modulation of acetylcholine release: receptor subtypes and possible mechanisms.
Kilbinger H; Schwörer H; Süss KD
EXS; 1989; 57():197-203. PubMed ID: 2533093
[No Abstract] [Full Text] [Related]
[Next] [New Search]
